Daclatasvir Dihydrochloride
Descriptio
Daclatasvir dihydrochloride (BMS 790052 dihydrochloride) est potens et viva voce activaHCV NS5A interduminhibitor cumEC50s range of 9-146 pM formultiple HCV replicon genotypes. Daclatasvir dihydrochloride etiam aorganicum anion traiciendum polypeptide 1B (OATP1B)etOATP1B3inhibitor cumIC50s 1.5 µM et 3.27 µM, respective.
IC50& Target
EC50: 50 pM (HCV replicon genotypum 1a), 9 pM (HCV replicon genotype 1b), 71 pM (HCV replicon genotypum 2a), 146 pM (HCV replicon genotypum 3a), 12 pM (HCV replicon genotypum 4a) et 33 pM ( HCV replicon genotype 5a)[1]
Kd: 8 nM (NS5A33-202) et 210 nM (NS5A26-202)[2]
IC50: 1.5 µM (OATP1B) et 3.27 µM (OATP1B3)[3]
in Vitro
Daclatasvir (BMS 790052) demonstrat potentem actionem inhibendi erga omnes genotypos probatos, cum EC.50valores vndique ab 9 pM ad 146 pM. Daclatasvir vetat HCV replicon genotypi 1a, 1b, 2a, 3a, 4a et 5a cum EC.50valores 50 pM, 9 pM, 71 pM, 146 pM, 12 pM et 33 pM resp. Daclatasvir potens est inhibitor viri genotypi JFH-1 2a infectious viri qui in cultura cellularum replicat (EC.50= 28 pM)[1]. Daclatasvir (BMS 790052) arcte obligat ad NS5A33-202 et NS5A26-202 cum Kds of 8 nM and 210 nM, respectively[2].
Repono
| Pulvis | -20°C | III annos |
| 4°C | II annis | |
| In solvendo | -80°C | VI menses |
| -20°C | I mensis |
Fusce Trial
| NCT Number | Sponsor | Conditio | Satus Date | Phase |
| NCT03369327 | Tehran University of Sciences Medical|RojanPharma Pharmaceutical Company | Hepatitis C Virus Infectio, Responsio ad Therapy de Viris Immunodeficiis Humanis | Ianuarii 1, 2017 | Phase 3 |
| NCT03485846 | R-Pharm|Almedis | Chronica Hepatitis C Genotype 1b | die 27 mensis Novembris anno 2017 | Phase 2 |
| NCT01016912 | Bristol-Myers Squibb | Hepatitis C Infection | December 2009 | Phase 2 |
| NCT01629732 | Bristol-Myers Squibb | Hepatitis C Virus | Martii 2013 | Phase 2 |
| NCT01497834 | Bristol-Myers Squibb | Hepatitis C | Ianuarii 2012 | Phase 3 |
| NCT01973049 | Bristol-Myers Squibb | Hepatitis C | December 2013 | Phase 3 |
| NCT00663208 | Bristol-Myers Squibb | Chronica Hepatitis C | May 2008 | Phase 2 |
| NCT02576314 | Humanity and Health Research Centre|Beijing 302 Hospital | Chronica Hepatitis C Infection | May 2015 | Phase 3 |
| NCT02756936 | Genuina Research Centrum, Aegyptus|Zeta Pharma Pharma Industriae | Sanus | Februarii 2016 | Phase 1 |
| NCT02771405 | National Hepatology & Tropical Medicine Research Institute|Cairo University | Hepatitis C, Chronic| | Martii 2016 | Phase 3 |
| NCT03706898 | Viriom | HIV-1-infectio|Hepatic Impairment | Octobris 1, 2018 | Phase 1 |
| NCT02319031 | Bristol-Myers Squibb | Hepatitis C | Februarii 2015 | Phase 3 |
| NCT02124044 | National Institute of Health Clinical Center (CC)|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb | HIV-HCV | Februarii 2014 | Phase 2 |
| NCT02551861 | Bristol-Myers Squibb | Hepatitis C | December 2015 | Phase 2 |
| NCT00859053 | Bristol-Myers Squibb | Insufficientia hepatis | Martius 2009 | Phase 1 |
| NCT01257204 | Bristol-Myers Squibb | Hepatitis C Virus | December 2010 | Phase 2 |
| NCT03063879 | University of Sciences Medical Tehran|Ahvaz Jundishapur University of Medical Sciences|Shiraz University of Medical Sciences|Hamadan University of Medical Sciences | Hepatitis C, Chronic|Chronic Renal Defectum | Aprilis 1, 2017 | Phase 4 |
| NCT01017575 | Bristol-Myers Squibb | Hepatitis C Infection | December 2009 | Phase 2 |
| NCT02865369 | Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital | Chronica Hepatitis C | September 2016 |
|
| NCT04070235 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Hepatitis C, Chronic | Die 29 Martii, 2019 | Phase 2|Phase 3 |
| NCT03487848 | Bristol-Myers Squibb | Hepatitis C|Chronic Hepatitis | May 18, 2018 | Phase 2 |
| NCT00904059 | Bristol-Myers Squibb | Hepatitis C | May 2009 | Phase 1 |
| NCT02107365 | Francis National Institute for Health and Medical Research National Agency for Research in AIDS and Virales Hepatitis (Inserm-ANRS) |Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | November 2013 | Phase 2 |
| NCT02397395 | Janssen R&D Ireland | Renal Impairment|End-stage Renal Disease | May 2015 | Phase 2 |
| NCT03169348 | Assiut University | Hepatitis C | Novembris 1, 2017 | Non Lorem |
| NCT02323594 | Bristol-Myers Squibb | Hepatitis C Infection | December MMXIV | Phase 1 |
| NCT03537196 | Institutum Nationale Gallicum pro Health et Medical Investigationis Nationalis Procuratio pro Inquisitione Gallica de AIDS et Hepatitis Viralis (Inserm-ANRS) | Hepatitis C|Drug Use|Viral Hepatitis C | November 13, 2018 | Phase 4 |
| NCT02103569 | Bristol-Myers Squibb | Hepatitis C | Aprilis MMXIV | Phase 1 |
| NCT02772744 | Zagazig University| | Hepatitis C | Novembris 1, 2017 |
|
| NCT01718158 | Bristol-Myers Squibb | Hepatitis C | Ianuarii 2013 | Phase 3 |
| NCT02496078 | Bristol-Myers Squibb | Hepatitis C | August 2015 | Phase 3 |
| NCT01425970 | Bristol-Myers Squibb | Hepatitis C | May 2012 | Phase 2 |
| NCT01471574 | Bristol-Myers Squibb | Hepatitis C, Genotype 1 | December 2011 | Phase 3 |
| NCT01573351 | Bristol-Myers Squibb | Hepatitis C Virus | May 2012 | Phase 3 |
| NCT01938625 | Janssen R&D Ireland | Hepatitis C, Chronic | December 12, 2013 | Phase 2 |
| NCT01492426 | Bristol-Myers Squibb | Hepatitis C | Ianuarii 2012 | Phase 3 |
| NCT03480932 | Johns Hopkins Bloomberg School of Public Health|Institutum Nationale de medicamentis ex abusu (NIDA)|YR Gaitonde Center for AIDS Research and Education | Hepatitis C, Chronic | Februarii 2, 2018 | Phase 2|Phase 3 |
| NCT03163849 | Assiut University | Chronica Hepatitis c | Septembris 1, 2019 | Phase 3 |
| NCT01581203 | Bristol-Myers Squibb | Hepatitis C Virus | May 2012 | Phase 3 |
| NCT01492504 | Bristol-Myers Squibb | Hepatitis C | Februarii 7, 2012 |
|
| NCT03686722 | Mohamed Raslan|Ain Shams University|Drug Research Centre, Cairo, Egypt | Diabetes Mellitus, Type 2|Hepatitis C|Drug Interactions | September 9, 2017 | Phase 1 |
| NCT02262728 | Janssen Research & Development, LLC | Hepatitis C, Chronic | September 30, 2014 | Phase 2 |
| NCT02349048 | Janssen Research & Development, LLC | Hepatitis C Virus | Ianuarii 2015 | Phase 2 |
| NCT03882307 | Assiut University | Hepatitis C, Chronic | May 2020 | Mane Phase 1 |
| NCT02758509 | Parc de Salut Mar | Chronica Hepatitis C|Cirrhosis | Ianuarii 1, 2010 |
|
| NCT01795911 | Bristol-Myers Squibb | Hepatitis C | Martii 2013 | Phase 2 |
| NCT03549832 | Assiut University|Sohag University|Meridionalis Valley University | HCV Coinfection | Ianuarii 1, 2018 | Non Lorem |
| NCT02161939 | Bristol-Myers Squibb | Chronica Hepatitis C |
| |
| NCT01309932 | Bristol-Myers Squibb | Hepatitis C | Martii 2011 | Phase 2 |
| NCT01995266 | Bristol-Myers Squibb | Hepatitis C | Februarii 28, 2014 | Phase 3 |
| NCT02640157 | AbbVie | Chronica Hepatitis C | | December 2015 | Phase 3 |
| NCT02032875 | Bristol-Myers Squibb | Hepatitis C | Martii 2014 | Phase 3 |
| NCT02624063 | Universitas Foederalis São Paulo | Hepatitis C, Chronic | December 2015 | Phase 4 |
| NCT00546715 | Bristol-Myers Squibb | Chronica Hepatitis C | Novembris 2007 | Phase 1|Phase 2 |
| NCT01718145 | Bristol-Myers Squibb | Hepatitis C Virus Infection | November 2012 | Phase 3 |
| NCT01616524 | Bristol-Myers Squibb | Hepatitis C Virus (HCV) | Iulii 2012 | Phase 3 |
| NCT02032901 | Bristol-Myers Squibb | Hepatitis C | Ianuarii 2014 | Phase 3 |
| NCT03540212 | Ain Shams University | Chronica HCV Infection | December 10, 2017 | Phase 2|Phase 3 |
| NCT02097966 | Bristol-Myers Squibb | Chronica Hepatitis C |
| |
| NCT02596880 | Tehran University of Sciences Medical | Hepatitis C|Cirrhosis | September 2015 | Phase 3 |
| NCT04019717 | Atea Pharmaceuticals, Inc. | Hepatitis C | Hepatitis C , Chronic | Chronic Hepatitis C | | die 20 mensis Iunii MMXIX | Phase 2 |
| NCT02992457 | Tanta University | Hepatitis C | Ianuarii 2015 | Phase 4 |
| NCT03547895 | Zagazig University | Decompensated Cirrhosis | Iunii 1, 2015 | Non Lorem |
| NCT03004625 | Kaohsiung Universitas Medical Chung-Ho Hospitalis Memorial|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterani Hospitalis Generalis, Taiwan|Sina University Hospitalis Medical University |National Cheng-Kung University Hospital | Hepatitis C | November 2016 | Phase 3 |
| NCT01051414 | Bristol-Myers Squibb | Hepatitis C Infection | April 2010 | Phase 2 |
| NCT02309450 | Francis National Institute for Health and Medical Research National Agency for Research in AIDS and Virales Hepatitis (Inserm-ANRS) |Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | December MMXIV | Phase 2 |
| NCT01628692 | Bristol-Myers Squibb|Janssen Research & Development, LLC | Hepatitis C Virus | Iulii 2012 | Phase 2 |
| NCT03186313 | Hospitalis Jecur Aegyptium|Wadi El Nil Hospital | Hepatitis C | September 2016 | Phase 3 |
| NCT03063723 | Tertium hospitale affiliatum, sol universitatis Yat-Sen | Chronica Hepatitis C (Disorder) | Ianuarii 1, 2016 |
|
| NCT00983957 | Bristol-Myers Squibb | Chronica Hepatitis C | October 2009 | Phase 1 |
| NCT01725542 | Francis National Institute for Health and Medical Research National Agency for Research in AIDS and Virales Hepatitis (Inserm-ANRS) |Bristol-Myers Squibb | HCV-HIV Co-Infection | Decembris 2012 | Phase 2 |
| NCT02282709 | Fundamentum pro Jecur Research | Chronica Hepatitis C | Februarii 2014 | Phase 3 |
| NCT02032888 | Bristol-Myers Squibb | Hepatitis C | Februarii 2014 | Phase 3 |
| NCT03247296 | MTI University | Hepatitis C | Februarii 28, 2017 |
|
| NCT01389323 | Bristol-Myers Squibb | Hepatitis C | September 2011 | Phase 3 |
| NCT02556086 | Bristol-Myers Squibb | Hepatitis C | December 2015 | Phase 2 |
| NCT01741545 | Bristol-Myers Squibb | Hepatitis C Virus | Martii 31, 2013 | Phase 3 |
| NCT01866930 | Bristol-Myers Squibb | Chronica Hepatitis C Infection | 11 Iulii 2013 | Phase 3 |
| NCT02268864 | Janssen-Cilag International NV | Hepatitis C, Chronic | Ianuarii 2015 | Phase 2 |
| NCT01278848 | Bristol-Myers Squibb | Hepatitis C | Iunii 2014 | Phase 3 |
| NCT03166280 | Eman Sayed Assen Abd Allah | Assiut University | Hepatitis C | Iunii 2017 |
|
| NCT02159352 | Bristol-Myers Squibb | Hepatitis C | Iunii 2014 | Phase 1 |
| NCT01125189 | Bristol-Myers Squibb | Hepatitis C Virus | July 2010 | Phase 2 |
| NCT03748745 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Medicamento Interactiones | November 19, 2018 | Phase 1 |
| NCT01012895 | Bristol-Myers Squibb | Chronica Hepatitis C | December 2009 | Phase 2 |
| NCT02565888 | Radboud University | Hepatitis C|HIV | November 2015 | Phase 1 |
| NCT02555943 | Humanity and Health Research Centre|Beijing 302 Hospital|Nanfang Hospital of Southern Medical University | Chronica Hepatitis C Infection|HBV Coinfection|Hepatitis B Reactivation | Februarii 2015 | Phase 2|Phase 3 |
| NCT02304159 | Tarek I. Hassanein, MD, FACP, FAG, AGAF|Southern California Research Center | Hepatitis C|Cirrhosis | Ianuarii 2015 | Phase 4 |
| NCT02580474 | Myeong Jun Song | Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam University Hospital|Konyang University Hospital | , Korea|Severance Hospital|Korea University Guro Hospital|Eulji Hospital | | Hepatitis C | Februarii 2016 | Phase 4 |
| NCT02104843 | Bristol-Myers Squibb | Hepatitis C | Aprilis MMXIV | Phase 1 |
| NCT01428063 | Bristol-Myers Squibb | Hepatitis C Virus Infection | September 2011 | Phase 2 |
| NCT02123654 | Bristol-Myers Squibb | Hepatitis C Virus Infection | Aprilis MMXIV | Phase 3 |
| NCT02565862 | Radboud University | Hepatitis C|Diabetes Mellitus| | Ianuarii 2016 | Phase 1 |
| NCT04211844 | Ain Shams University | Chronica Hepatitis C | October 1, 2019 |
|
| NCT00874770 | Bristol-Myers Squibb | Hepatitis C Infection | Iunii 2009 | Phase 2 |
| NCT03883698 | Sanjay Gandhi Postgraduate Institute of Sciences Medical | Renum Defectum, Chronic|Hepatitis C | Martii 15, 2019 | Phase 3 |
| NCT01448044 | Bristol-Myers Squibb | Hepatitis C | December 2011 | Phase 3 |
| NCT01359644 | Bristol-Myers Squibb|Pharmasset | Chronica Hepatitis C | Iunii 2011 | Phase 2 |
| NCT01842451 | Vertex Pharmaceuticals Incorporatus | Hepatitis C | | Iunii 2013 | Phase 2 |
| NCT02762448 | Tainan Hospitalis municipalis | Hepatitis c | Iulii 2016 |
|
| NCT02473211 | Humanity and Health Research Centre|Beijing 302 Hospital | Chronica Hepatitis C Infection | Ianuarii 2015 | Phase 2|Phase 3 |
| NCT01455090 | Bristol-Myers Squibb | Chronica Hepatitis C | November 30, 2011 | Phase 2 |
| NCT03490097 | Ain Shams University | Chronica Hepatitis c| | December 1, 2017 | Phase 2|Phase 3 |
| NCT01170962 | Bristol-Myers Squibb | Hepatitis C Virus | August 2010 | Phase 2 |
| NCT02333292 | Valme University Hospital|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias| Hospitalis Generalis Universitario de Alicante | Hospital Royo Vilanova | Hospital Universitario de Burgos | Complejo Hospitalario Universitario de Huelva | Hospital Universitario Reina Sofia de Cordoba | Hospital Universitario Virgen Macarena | Complexo Hospitalario Universitario de Vigo | Clinica Universidad de Navarra , Universidad de Navarra | Hospital Clinico Universitario San Celilio | Hospitalis Universitario La Fe | de Valentia|Hospitali Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospitali Generali Universitario Sanctae Lucía|Centro Penitenciario Alicante 1|Hospitale Regionali Universitario Carlos Haya | Chronica Hepatitis C Infection | December MMXIV |
|
| NCT03200184 | Tehran University of Sciences Medical | Hepatitis C | Septembris 1, 2016 | Phase 4 |
| NCT03188276 | Tertium hospitale affiliatum, sol universitatis Yat-Sen | Chronica Hepatitis C | Februarii 1, 2016 | Mane Phase 1 |
| NCT01830205 | Bristol-Myers Squibb | Hepatitis C | Septembris 2012 | Phase 1 |
Rogatio18Qualitas Constantia Aestimatio inceptis quae probaverunt4et6incepta approbantes.
Provectus qualitas internationalis administrationis systematis solidum fundamentum in venditionibus posuit.
Qualitas vigilantia percurrit totum vitae cyclum producti, ut qualitatem et therapeuticum effectum curet.
Negotiis professionales regulares turmas sustinet qualitatem postulatorum in applicatione et adnotatione.
Korea Countec Bottled Packaging linea
Taiwan CVC Bottled Packaging Line
Italia CAM Board Packaging Line
German Fette Compacting Machine
Iaponia Viswill Traba Detector
DCS Control Room
Cooperatio internationalis
Cooperatio domestica
Epistulam tuam hic scribe et mitte nobis
